银屑病治疗的当前挑战和新疗法综述。

IF 1 Q4 PHARMACOLOGY & PHARMACY
Ashish Kumar Parashar, Keshav Saini, Vandana Arora Sethi, Chitra Gupta
{"title":"银屑病治疗的当前挑战和新疗法综述。","authors":"Ashish Kumar Parashar, Keshav Saini, Vandana Arora Sethi, Chitra Gupta","doi":"10.2174/0115748871393960250912053926","DOIUrl":null,"url":null,"abstract":"<p><p>Psoriasis is a chronic inflammatory skin disorder that presents ongoing challenges in its management. Current therapeutic approaches, including topical agents, phototherapy, systemic immunomodulators, and biologics, focus on symptom alleviation and improving patients' quality of life. Nonetheless, several limitations exist, such as adverse effects associated with treatments, the emergence of resistance, high costs, and significant inter-individual variability in therapeutic responses. Recent advancements in psoriasis management show promise in developing novel therapeutic agents. Biologics targeting underexploited pathways, particularly interleukin-23 inhibitors like lebrikizumab, have shown superior efficacy profiles. Small molecule inhibitors, such as RORγt and ROCK2 inhibitors, have broadened the therapeutic landscape. Combination regimens, including biologics in conjunction with methotrexate, may enhance overall treatment efficacy. Innovations in topical drug delivery systems, particularly through the use of microneedles and nanoparticle-based carriers, provide the potential for improved therapeutic outcomes. Moreover, the integration of biomarkers and multi-omics approaches holds substantial promise for personalized treatment strategies, refining diagnostic precision and predicting treatment responses while guiding therapeutic decisions. Collaborating among researchers, clinicians, and industry stakeholders is crucial to translating these scientific advancements into clinical practice. By addressing existing challenges and leveraging these emerging therapies, we can significantly enhance the management of psoriasis and improve patient outcomes for this chronic condition.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Review on Current Challenges and Emerging Therapies in Psoriasis Management.\",\"authors\":\"Ashish Kumar Parashar, Keshav Saini, Vandana Arora Sethi, Chitra Gupta\",\"doi\":\"10.2174/0115748871393960250912053926\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Psoriasis is a chronic inflammatory skin disorder that presents ongoing challenges in its management. Current therapeutic approaches, including topical agents, phototherapy, systemic immunomodulators, and biologics, focus on symptom alleviation and improving patients' quality of life. Nonetheless, several limitations exist, such as adverse effects associated with treatments, the emergence of resistance, high costs, and significant inter-individual variability in therapeutic responses. Recent advancements in psoriasis management show promise in developing novel therapeutic agents. Biologics targeting underexploited pathways, particularly interleukin-23 inhibitors like lebrikizumab, have shown superior efficacy profiles. Small molecule inhibitors, such as RORγt and ROCK2 inhibitors, have broadened the therapeutic landscape. Combination regimens, including biologics in conjunction with methotrexate, may enhance overall treatment efficacy. Innovations in topical drug delivery systems, particularly through the use of microneedles and nanoparticle-based carriers, provide the potential for improved therapeutic outcomes. Moreover, the integration of biomarkers and multi-omics approaches holds substantial promise for personalized treatment strategies, refining diagnostic precision and predicting treatment responses while guiding therapeutic decisions. Collaborating among researchers, clinicians, and industry stakeholders is crucial to translating these scientific advancements into clinical practice. By addressing existing challenges and leveraging these emerging therapies, we can significantly enhance the management of psoriasis and improve patient outcomes for this chronic condition.</p>\",\"PeriodicalId\":21174,\"journal\":{\"name\":\"Reviews on recent clinical trials\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2025-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reviews on recent clinical trials\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0115748871393960250912053926\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews on recent clinical trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748871393960250912053926","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

牛皮癣是一种慢性炎症性皮肤病,在其管理中呈现出持续的挑战。目前的治疗方法,包括局部药物、光疗、全身免疫调节剂和生物制剂,重点是减轻症状和改善患者的生活质量。尽管如此,仍存在一些限制,例如与治疗相关的不良反应、耐药性的出现、高成本以及治疗反应的显著个体差异。银屑病治疗的最新进展显示出开发新型治疗药物的希望。靶向未开发途径的生物制剂,特别是白介素-23抑制剂,如lebrikizumab,已经显示出优越的疗效。小分子抑制剂,如rorγ - t和ROCK2抑制剂,已经拓宽了治疗领域。联合治疗方案,包括生物制剂与甲氨蝶呤联合使用,可以提高整体治疗效果。局部给药系统的创新,特别是通过使用微针和基于纳米颗粒的载体,为改善治疗结果提供了潜力。此外,生物标志物和多组学方法的整合为个性化治疗策略、提高诊断精度和预测治疗反应提供了巨大的希望,同时指导治疗决策。研究人员、临床医生和行业利益相关者之间的合作对于将这些科学进步转化为临床实践至关重要。通过解决现有的挑战和利用这些新兴疗法,我们可以显著加强牛皮癣的管理,改善这种慢性疾病的患者预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A Review on Current Challenges and Emerging Therapies in Psoriasis Management.

Psoriasis is a chronic inflammatory skin disorder that presents ongoing challenges in its management. Current therapeutic approaches, including topical agents, phototherapy, systemic immunomodulators, and biologics, focus on symptom alleviation and improving patients' quality of life. Nonetheless, several limitations exist, such as adverse effects associated with treatments, the emergence of resistance, high costs, and significant inter-individual variability in therapeutic responses. Recent advancements in psoriasis management show promise in developing novel therapeutic agents. Biologics targeting underexploited pathways, particularly interleukin-23 inhibitors like lebrikizumab, have shown superior efficacy profiles. Small molecule inhibitors, such as RORγt and ROCK2 inhibitors, have broadened the therapeutic landscape. Combination regimens, including biologics in conjunction with methotrexate, may enhance overall treatment efficacy. Innovations in topical drug delivery systems, particularly through the use of microneedles and nanoparticle-based carriers, provide the potential for improved therapeutic outcomes. Moreover, the integration of biomarkers and multi-omics approaches holds substantial promise for personalized treatment strategies, refining diagnostic precision and predicting treatment responses while guiding therapeutic decisions. Collaborating among researchers, clinicians, and industry stakeholders is crucial to translating these scientific advancements into clinical practice. By addressing existing challenges and leveraging these emerging therapies, we can significantly enhance the management of psoriasis and improve patient outcomes for this chronic condition.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Reviews on recent clinical trials
Reviews on recent clinical trials PHARMACOLOGY & PHARMACY-
CiteScore
3.10
自引率
5.30%
发文量
44
期刊介绍: Reviews on Recent Clinical Trials publishes frontier reviews on recent clinical trials of major importance. The journal"s aim is to publish the highest quality review articles in the field. Topics covered include: important Phase I – IV clinical trial studies, clinical investigations at all stages of development and therapeutics. The journal is essential reading for all researchers and clinicians involved in drug therapy and clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信